个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Qu, Lihui[1,2,3,4] * ; Lu, Yingying[1,2,3,4] ; Ying, Meike[1,2,3,4] ; Li, Bingjue[1,2,3,4] ; Weng, Chunhua[1,2,3,4] ; Xie, Zhoutao[1,2,3,4] ; Liang, Ludan[1,2,3,4] ; Lin, Chuan[1,2,3,4] ; Yang, Xian[1,2,3,4] ; Feng, Shi[1,2,3,4] ; Wang, Yucheng[1,2,3,4] ; Shen, Xiujin[1,2,3,4] ; Zhou, Qin[1,2,3,4] ; Chen, Ying[1,2,3,4] ; Chen, Zhimin[1,2,3,4] ; Wu, Jianyong[1,2,3,4] ; Lin, Weiqiang[1,2,3,4,9] ; Shen, Yi[8] ; Qin, Jing[5,7] ; Xu, Hang[5] ; Xu, Feng[5,7] ; Wang, Junwen[6,8,1] ; Chen, Jianghua[1,2,3,4] ; Jiang, Hong[1,2,3,4] ; Huang, Hongfeng[1,2,3,4] ;
机构： [1]Zhejiang Univ, Affiliated Hosp 1, Coll Med, Kidney Dis Ctr, Hangzhou, Zhejiang, Peoples R China [2]State Adm Tradit Chinese Med PR China, Kidney Dis Immunol Lab, Grade Lab 3, Hangzhou, Zhejiang, Peoples R China [3]Minist Hlth, Key Lab Multiple Organ Transplantat, Hangzhou, Zhejiang, Peoples R China [4]Key Lab Nephropathy, Hangzhou, Zhejiang, Peoples R China [5]Univ Hong Kong, LKS Fac Med, Dept Biochem, Hong Kong, Hong Kong, Peoples R China [6]Univ Hong Kong, LKS Fac Med, Ctr Genom Sci, Hong Kong, Hong Kong, Peoples R China [7]Univ Hong Kong, Shenzhen Inst Res & Innovat, Shenzhen, Guangdong, Peoples R China [8]Zhejiang Univ, Dept Epidemiol, Coll Med, Hangzhou, Zhejiang, Peoples R China [9]Zhejiang Univ, Inst Translat Med, Coll Med, Hangzhou, Zhejiang, Peoples R China
出处：
DOI： 10.18632/oncotarget.18150

关键词： CYP3A5 FK506 renal transplantation acute rejection

摘要：
Tacrolimus (FK506) and cyclosporine A (CsA) are widely used to protect graft function after renal transplantation. The aim of the present study is to determine whether the single nucleotide polymorphism of CYP3A5 is a predictive index of FK506 dose requirement, and also the selection yardstick of FK506 or CsA treatment. We tested archival peripheral blood of 218 kidney recipients for CYP3A5 genotyping with PCR-SSP. Meanwhile, the dose of FK506 and CsA was recorded, blood concentration of the drugs was measured, and graft outcome was monitored. These results indicate that CYP3A5*AA/AG carriers need higher FK506 dose than CYP3A5*GG homozygote to achieve the target blood concentration. For CYP3A5*GG carriers, taking FK506 or CsA are both advisable. CYP3A5*AA/AG carriers preferred to CsA treatment depending on the graft outcomes and drug costs. CYP3A5 genotyping is a new approach to detecting FK506 dose requirement and a predictive index for the FK506 or CsA treatment selection in kidney recipients.

基金：
National Fund Committee of China [81470938, 81200546]; Dr Cheng Yu Tung Fellowships
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2016]版：
大类 | 1 区 医学
小类 | 2 区 细胞生物学 2 区 肿瘤学
最新[2025]版：
无
JCR分区：
出版当年[2015]版：
Q1 CELL BIOLOGY Q1 ONCOLOGY
最新[2023]版：
无

影响因子： 最新[2023版] 最新五年平均 出版当年[2015版] 出版当年五年平均 出版前一年[2014版] 出版后一年[2016版]

第一作者：
第一作者机构： [1]Zhejiang Univ, Affiliated Hosp 1, Coll Med, Kidney Dis Ctr, Hangzhou, Zhejiang, Peoples R China [2]State Adm Tradit Chinese Med PR China, Kidney Dis Immunol Lab, Grade Lab 3, Hangzhou, Zhejiang, Peoples R China [3]Minist Hlth, Key Lab Multiple Organ Transplantat, Hangzhou, Zhejiang, Peoples R China [4]Key Lab Nephropathy, Hangzhou, Zhejiang, Peoples R China
通讯作者：
通讯机构： [1]Zhejiang Univ, Affiliated Hosp 1, Coll Med, Kidney Dis Ctr, Hangzhou, Zhejiang, Peoples R China [2]State Adm Tradit Chinese Med PR China, Kidney Dis Immunol Lab, Grade Lab 3, Hangzhou, Zhejiang, Peoples R China [3]Minist Hlth, Key Lab Multiple Organ Transplantat, Hangzhou, Zhejiang, Peoples R China [4]Key Lab Nephropathy, Hangzhou, Zhejiang, Peoples R China [6]Univ Hong Kong, LKS Fac Med, Ctr Genom Sci, Hong Kong, Hong Kong, Peoples R China [8]Zhejiang Univ, Dept Epidemiol, Coll Med, Hangzhou, Zhejiang, Peoples R China
推荐引用方式(GB/T 7714)：
Qu Lihui,Lu Yingying,Ying Meike,et al.Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients[J].ONCOTARGET.2017,8(46):81285-81294.doi:10.18632/oncotarget.18150.
APA：
Qu, Lihui,Lu, Yingying,Ying, Meike,Li, Bingjue,Weng, Chunhua...&Huang, Hongfeng.(2017).Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients.ONCOTARGET,8,(46)
MLA：
Qu, Lihui,et al."Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients".ONCOTARGET 8..46(2017):81285-81294

相关文献

[1]Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients [2]Allogeneic mesenchymal stem cell as induction therapy to prevent both delayed graft function and acute rejection in deceased donor renal transplantation: study protocol for a randomized controlled trial [3]Allogeneic mesenchymal stem cells as induction therapy are safe and feasible in renal allografts: pilot results of a multicenter randomized controlled trial [4]Allogeneic Mesenchymal Stem Cells as Induction Therapy Are Safe and Feasible in Renal Allografts: Pilot Results of a Multicenter Randomized Controlled Trial. [5]Washed microbiota transplantation improves renal function in patients with renal dysfunction: a retrospective cohort study [6]Pharmacokinetics of Sugammadex for the Reversal of Moderate Neuromuscular Blockade in Patients During Renal Transplantation [7]改进的套袖法吻合肾动脉建立大鼠原位肾移植模型 [8]IL-35 induces immune tolerance in renal transplantation rats by modulating CD4+CD25+regulatory T-cells [9]A randomized controlled trial to evaluate efficacy and safety of early conversion to a low-dose calcineurin inhibitor combined with sirolimus in renal transplant patients [10]乙型肝炎表面抗原阳性患者肾移植21例

资源点击量：2018 今日访问量：0 总访问量：645 更新日期：2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持：重庆聚合科技有限公司 地址：广州市越秀区大德路111号